The pathway mTOR, a key mediator of phosphatidyl-inositol-3-kinase (PI3K) signaling, has emerged as a compelling molecular target in glioblastoma patients, although clinical efforts to target mTOR have not been successful. This evidence concerns the gene MTOR and glioblastoma.